The Global Health Expenditure Report delves into the intricate landscape of global economies and health systems. This year, it focuses on health spending in 2022, the third year of the COVID-19 pandemic. It shows how countries around the world responded to the health and economic shocks of the pande...mic from a financial perspective. It also considers what the future may hold as countries emerge from the pandemic. Although it is still too early to gauge whether the COVID-19 pandemic has altered long-term trends in health spending, spending appears to have peaked and is now at or below its long-term rising trend in most country income groups. Additionally, to mark the 25th anniversary of the World Health Organization’s (WHO) Health Expenditure Tracking Program, the report reviews the program’s achievements and envisions a path forward. As the program’s lead technical agency, WHO is committed to working closely with partners to support countries in tracking health spending and sustaining the Global Health Expenditure Database and the Global Health Expenditure Report as global public goods.
more
La Stratégie Nationale de Plaidoyer et de Mobilisation des Ressources en faveur de la Lutte contre le Paludisme 2024–2028 en République Démocratique du Congo vise à renforcer l’engagement politique, mobiliser des financements domestiques et internationaux et impliquer tous les secteurs (publ...ic, privé, société civile) pour réduire la mortalité liée au paludisme de 70 % et l’incidence de 50 % d’ici 2028.
Le document propose des actions concrètes : plaidoyer auprès des décideurs pour des budgets accrus, exonération des intrants antipaludiques, introduction du vaccin R21/Matrix-M, création de partenariats public-privé, implication des leaders communautaires et campagnes de sensibilisation via les médias. Il s’aligne sur la stratégie mondiale de l’OMS et promeut une approche multisectorielle, coordonnée par le Programme National de Lutte contre le Paludisme avec l’appui de partenaires comme l’USAID et Breakthrough ACTION.
more
The WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) was launched in 2015 to foster AMR surveillance and inform strategies to contain AMR. The system started with surveillance of AMR in bacteria causing common human infections and has expanded its scope to include surveillance... of antimicrobial consumption (AMC), invasive fungal infections, and a One Health surveillance model relevant to human health. To meet future challenges, it is in continuous evolution to enhance the quality and representativeness of data to inform the AMR burden accurately. As of the end of 2022, 127 countries, territories and areas participate in GLASS.
The fifth GLASS report, produced in collaboration with Member States, summarizes 2020 data on AMR rates in common bacteria from countries, territories, and areas. The report brings new features, including analyses of population testing coverage or AMR trends. For the first time, the report presents 2020 data on AMC at the national level. A new interactive dashboard allow users to explore AMR and AMC global data, country profiles and download the data.
This report marks the end of the early implementation phase of GLASS. In addition to presenting data collected through the latest data call, this report provides a summary of five years of national AMR surveillance data contributed to GLASS from its initiation, presents AMR findings in the context of progress of country participation in GLASS and in global AMR surveillance coverage and laboratory quality assurance systems at (sub)national level.
Patterns of antimicrobial consumption are presented by country with a particular focus on antibacterials. The report also presents the antimicrobial consumption according to the WHO AWaRe antibiotic classification, for penicillins and cephalosporines. From a One Health perspective, the report presents antimicrobial consumption data in the human sector expressed in tons to allow a comparison with antimicrobial consumption from other sectors (not included in this report).
more
Afr J Thoracic Crit Care Med 2021;27(4):Published online 22 October 2021. https://doi.org/10.7196/AJTCCM.2021.v27i4.173
Este documento dá orientações sobre o uso de máscaras na comunidade durante a assistência domiciliar e em serviços de saúde em regiões que têm relatado casos de COVID-19. É dirigido a indivíduos na comunidade, profissionais de saúde pública e de prevenção e controle de infecção (PCI...), administradores da saúde, profissionais de saúde e trabalhadores da saúde comunitária. O documento será revisado à medida que mais dados se tornarem disponíveis.
more
21 августа 2020 г.
В этом документе представлены рекомендации для лиц, принимающих решения, работников общественного
здравоохранения и специалистов в области педиа...рии, касающиеся использования детских масок в условиях пандемии
COVID-19.
more
MMWR Morb Mortal Wkly Rep. ePub: 4 December 2020. DOI: http://dx.doi.org/10.15585/mmwr.mm6949e2
إرشادات مبدئ ّیة
6 نیسان/ أبریل 2020
Временные рекомендации
5 июня 2020 г
Ношение медицинской маски является одной из профилактических мер, которая может ограничить распространение ряда вирусных инф...кций, в том числе, COVID-19. Однако использования маски как единственного средства недостаточно для обеспечения адекватного уровня защиты, и следует принимать также другие меры. Независимо от применения масок первоочередное значение в профилактике передачи COVID-19 от человека к человеку имеет тщательное соблюдение гигиены рук и других мер ПИИК.
more
This second edition of the Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline provides the most up to date technical guidance on mask use in community settings in the context of COVID-19.
In this edition, new information includes updated mask re...commendations for children in community settings including updated age specific recommendations, statements for children with disabilities and those at high risk for complications related to COVID-19 infection. Updated implementation considerations for mask use in school settings are also included.
This living guideline is being published using the MAGICApp online publishing platform https://app.magicapp.org/#/guideline/Lr2a8L , as well as in PDF copy on the WHO website.
more
El documento "Lista de productos sanitarios prioritarios para la respuesta a COVID-19 y especificaciones técnicas asociadas" complementa esta directriz.
Este documento proporciona una orientación provisional sobre la calidad, las características de rendimiento y las normas conexas de los equi...pos de protección personal (EPP) que se utilizarán en el contexto de COVID-19. Esto incluye los productos sanitarios prioritarios de la OMS, concretamente: mascarillas quirúrgicas, mascarillas no quirúrgicas, guantes, gafas, protectores faciales, batas y mascarillas N95. Está dirigido a los organismos de adquisición, los departamentos de salud laboral, los departamentos o puntos focales de prevención y control de infecciones, los administradores de los centros de salud, la ingeniería biomédica y de materiales, los fabricantes de EPI y las autoridades de salud pública, tanto a nivel nacional como de los centros.
more
Ce document fournit des orientations provisoires sur la qualité, les caractéristiques de performance et les normes connexes des équipements de protection individuelle (EPI) à utiliser dans le contexte de COVID-19. Il s'agit notamment des dispositifs médicaux prioritaires de l'OMS, à savoir : l...es masques chirurgicaux, les masques non chirurgicaux, les gants, les lunettes de protection, les écrans faciaux, les blouses et les masques N95. Il est destiné aux organismes d'approvisionnement, aux services de santé au travail, aux services ou points focaux de prévention et de contrôle des infections, aux administrateurs d'établissements de santé, aux ingénieurs biomédicaux et des matériaux, aux fabricants d'EPI et aux autorités de santé publique, tant au niveau national qu'au niveau des établissements.
more
In 2014, an estimated 40 million women of reproductive age were infected with Schistosoma haematobium, S. japonicum and/or S. mansoni. In both 2003 and 2006, the World Health Organization (WHO) recommended that all schistosome-infected pregnant and breastfeeding women be offered treatment, with praz...iquantel, either individually or during treatment campaigns. In 2006, WHO also stated the need for randomized controlled trials to assess the safety and efficacy of such treatment. Some countries have yet to follow the recommendation on treatment and many programme managers and pregnant women in other countries remain reluctant to follow the recommended approach.
more
French and European food systems need to be trans- formed in order to address health, environmental and social challenges.
These guidelines are designed for ICRC and other health professionals – nurses, midwifes, doctors – who either lack experience in antenatal care or are not used to working in countries where medical infrastructure is underdeveloped or non-existent
Centre de traitement des infections respiratoires aiguës sévères : manuel pratique pour la mise en place et la gestion d’un centre de traitement des IRAS et d’une unité de dépistage des IRAS dans les établissements de soins
Ending Cholera—A Global Roadmap to 2030 operationalises the new global strategy for cholera control at the country level and provides a concrete path toward a world in which cholera is no longer a threat to public health